Positive results from phase I clinical trial of SMT D002 for the treatment of Seborrhoea
SMT D002 suppresses sebum levels by 90% in repeat-dose trial
Summit Corporation plc announced a positive outcome from its repeat-dose Phase I clinical trial of SMT D002, its candidate for the treatment of seborrhoea (excessive sebum production), a primary cause of acne.
The study was conducted in 18 healthy volunteers and examined the effect of repeat oral doses of SMT D002 over a four-day period. The key findings of the Phase I clinical trial are:
- Statistically significant levels of sebum suppression (primary endpoint) of 90% when compared to the placebo group (p=0.04)
- SMT D002 proved to be safe with no serious or unexpected adverse side-effects reported
- Sebum levels measured over six hours following treatment using a Sebumeter, an industry accepted method
- Results from trial support a previous positive Phase I single-dose study conducted in nine volunteers
The results of this trial confirm the potential of SMT D002 as a new therapeutic agent for the treatment of seborrhoea in acne patients. Summit plans to develop a topical formulation of SMT D002 to further evaluate its efficacy in the treatment of acne and the Company is actively seeking a commercial partner to advance this candidate from the clinic through to the market.
Most read news
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents

Infrareal takes over pharmaceutical and biotech site in Orth, Lower Austria from Takeda - "Our expertise will help us to further expand the site, and we are hoping to attract more companies from these industrie"
Sanofi Pasteur and Butantan Institute to Provide A(H1N1) Vaccine to Brazilian Government - Initial supply of 18 million doses of A(H1N1) influenza vaccine
A Trojan Horse delivery for treating a rare, potentially deadly, blood-clotting disorder - In this possible treatment, platelet blood cells carry an enzyme needed to prevent clots in TTP, while hiding the enzyme from autoantibody neutralization
CRELUX and ProQinase establish joint crystal-grade kinase protein and structures platform
Novel HCMV compound of AiCuris in phase IIb trial with bone marrow transplant recipients
Basilea receives milestone payment from distribution agreement for Toctino with Almirall
Biotage AB and McMaster University sign joint agreement to develop new chemistry platform
Asia-Pacific continues to drive global healthcare investment, innovation and growth ASEAN - A US$150 billion healthcare market by 2017, says Frost & Sullivan
Pharmacogenomics study finds rare gene variants critical for personalized drug treatment
